Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
David Combarel, Julie Tran, Julia Delahousse, Gilles Vassal & Angelo Paci. (2023) Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions. Expert Opinion on Drug Metabolism & Toxicology 19:2, pages 75-90.
Read now
Read now
Esmeralda C. Teo, Benigno C. Valdez, Jie Ji, Yang Li, Yan Liu, Jonathan E. Brammer, Chitra Hosing, Yago Nieto, Richard E. Champlin & Borje S. Andersson. (2016) Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leukemia & Lymphoma 57:11, pages 2644-2652.
Read now
Read now
Ioanna Sakellari, Despoina Mallouri, Ioannis Batsis, Chrysa Apostolou, Varnavas Konstantinou, Eleni-Maria Abela, Vasiliki Douka, Anastasia Marvaki, Kyriakos Karypidis, Michalis Iskas, Panayiotis Baliakas, Panayotis Kaloyannidis, Evangelia Yannaki, Damianos Sotiropoulos, Giorgos Kouvatseas, Christos Smias & Achilles Anagnostopoulos. (2015) Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Leukemia & Lymphoma 56:11, pages 3071-3081.
Read now
Read now
Guiyun Song, Benigno C. Valdez, Yang Li, Jose R. Dominguez, Paul Corn, Richard E. Champlin & Borje S. Andersson. (2014) The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leukemia & Lymphoma 55:7, pages 1625-1634.
Read now
Read now
Articles from other publishers (16)
Gheath Alatrash, Chantal Saberian, Roland Bassett, Peter F. Thall, Celina Ledesma, Yoshimi Lu, May Daher, Benigno C. Valdez, Jitesh Kawedia, Uday Popat, Rohtesh Mehta, Betul Oran, Yago Nieto, Amanda Olson, Paolo Anderlini, David Marin, Chitra Hosing, Amin M. Alousi, Elizabeth J. Shpall, Gabriela Rondon, Julianne Chen, Muzaffar Qazilbash, Richard E. Champlin & Partow Kebriaei. (2022) Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplantation and Cellular Therapy 28:8, pages 501.e1-501.e7.
Crossref
Crossref
N. M. Bobrova & T. V. Romanovskaya. (2022) Mechanisms of Drug Resistance in Acute Myeloid Leukemia. Biology Bulletin Reviews 11:S1, pages 32-46.
Crossref
Crossref
G Damaj, J Cornillon, K Bouabdallah, R Gressin, S Vigouroux, T Gastinne, F Ranchon, H Ghésquières, G Salles, I Yakoub-Agha & E Gyan. (2017) Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Bone Marrow Transplantation 52:7, pages 941-949.
Crossref
Crossref
Partow Kebriaei, Roland Bassett, Genevieve Lyons, Ben Valdez, Celina Ledesma, Gabriela Rondon, Betul Oran, Stefan Ciurea, Amin Alousi, Uday Popat, Krina Patel, Sairah Ahmed, Amanda Olson, Qaiser Bashir, Nina Shah, Roy Jones, David Marin, Katayoun Rezvani, Yago Nieto, Issa Khouri, Muzaffar Qazilbash, Chitra Hosing, Elizabeth Shpall, Richard E. Champlin & Borje S. Andersson. (2017) Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biology of Blood and Marrow Transplantation 23:2, pages 285-292.
Crossref
Crossref
William B. Parker & Varsha Gandhi. 2017. Chemotherapy for Leukemia. Chemotherapy for Leukemia
261
286
.
Jie Ji, Benigno C. Valdez, Yang Li, Yan Liu, Esmeralda C. Teo, Yago Nieto, Richard E. Champlin & Borje S. Andersson. (2016) Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Experimental Hematology 44:6, pages 458-465.
Crossref
Crossref
Dong-Yeop Shin, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Jee Hyun Kong, Jeong-A Kim, Byung-Su Kim, Hyo Jung Kim, Jong-Ho Won, Sung-Kyu Park & Won Seog Kim. (2016) Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Cancer Chemotherapy and Pharmacology 77:4, pages 865-873.
Crossref
Crossref
Borje S. Andersson, Benigno C. Valdez & Roy B. Jones. 2015. Thomas’ Hematopoietic Cell Transplantation. Thomas’ Hematopoietic Cell Transplantation
211
224
.
Julien Valton, Valérie Guyot, Alan Marechal, Jean-Marie Filhol, Alexandre Juillerat, Aymeric Duclert, Philippe Duchateau & Laurent Poirot. (2015) A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy. Molecular Therapy 23:9, pages 1507-1518.
Crossref
Crossref
Guiyun Song, Benigno C. Valdez, Yang Li, Yan Liu, Richard E. Champlin & Borje S. Andersson. (2014) Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications–Positive Acute Myeloid Leukemia Cells. Biology of Blood and Marrow Transplantation 20:11, pages 1687-1695.
Crossref
Crossref
Emily Wang, Alison Gulbis, James W. Hart & Yago Nieto. (2014) The Emerging Role of Gemcitabine in Conditioning Regimens for Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 20:9, pages 1382-1389.
Crossref
Crossref
I.H. Bartelink, E.M.L. van Reij, C.E. Gerhardt, E.M. van Maarseveen, A. de Wildt, B. Versluys, C.A. Lindemans, M.B. Bierings & Jaap Jan Boelens. (2014) Fludarabine and Exposure-Targeted Busulfan Compares Favorably with Busulfan/Cyclophosphamide-Based Regimens in Pediatric Hematopoietic Cell Transplantation: Maintaining Efficacy with Less Toxicity. Biology of Blood and Marrow Transplantation 20:3, pages 345-353.
Crossref
Crossref
Benigno C. Valdez, Guiyun Wang, David Murray, Yago Nieto, Yang Li, Jatin Shah, Francesco Turturro, Michael Wang, Donna M. Weber, Richard E. Champlin, Muzaffar H. Qazilbash & Borje S. Andersson. (2013) Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. Experimental Hematology 41:8, pages 719-730.
Crossref
Crossref
Partow Kebriaei, Roland Basset, C. Ledesma, S. Ciurea, S. Parmar, E.J. Shpall, C. Hosing, Issa Khouri, M. Qazilbash, U. Popat, A. Alousi, Y. Nieto, R.B. Jones, M. de Lima, R.E. Champlin & Borje S. Andersson. (2012) Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 18:12, pages 1819-1826.
Crossref
Crossref
Yago Nieto, Peter Thall, Ben Valdez, Borje Andersson, Uday Popat, Paolo Anderlini, Elizabeth J. Shpall, Roland Bassett, Amin Alousi, Chitra Hosing, Partow Kebriaei, Muzaffar Qazilbash, Erin Frazier, Alison Gulbis, Christina Chancoco, Qaiser Bashir, Stefan Ciurea, Issa Khouri, Simrit Parmar, Nina Shah, Laura Worth, Gabriela Rondon, Richard Champlin & Roy B. Jones. (2012) High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. Biology of Blood and Marrow Transplantation 18:11, pages 1677-1686.
Crossref
Crossref
Benigno C. Valdez, Yago Nieto, David Murray, Yang Li, Guiyun Wang, Richard E. Champlin & Borje S. Andersson. (2012) Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Experimental Hematology 40:10, pages 800-810.
Crossref
Crossref